Source:http://linkedlifedata.com/resource/pubmed/id/21570434
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
29-30
|
| pubmed:dateCreated |
2011-6-13
|
| pubmed:abstractText |
An optimal cancer vaccine should be able to induce highly potent, long-lasting, tumor-specific responses in the majority of the cancer patient population. One approach for achieving this is to use synthetic peptide vaccines derived from widely expressed tumor-associated antigens, that promiscuously bind multiple MHC class I and class II alleles. MUC1-SP-L (ImMucin, VXL100) is a 21mer peptide encoding the complete signal peptide domain of MUC1, a tumor-associated antigen expressed by over 90% of solid and non-solid tumors. MUC1-SP-L was predicted in silico to bind various MHC class I and MHC class II alleles, covering the majority of the Caucasian population. PBLs obtained from 13 naïve donors all proliferated, with a Stimulation Index (SI?2), to the MUC1-SP-L peptide, producing mixed CD4+ and CD8+ responses. Similar results were manifested by MUC1-SP-L in PBLs derived from 9 of 10 cancer patients with MUC1 positive tumors. CD4+ and CD8+ T cell populations exhibited CD45RO memory markers and secreted IFN-gamma and IL-2 following stimulation with MUC1-SP-L. These T cells also exhibited proliferation to the MUC1-SP-L inner 9mer epitopes and cytotoxicity against tumor cell lines expressing MUC1 and a concordant MHC class I allele. Cytotoxicity to MUC1-expressing human and murine tumors was shown also in T cells obtained from HLA-A2 transgenic mice and BALB/c syngeneic mice immunized with the MUC1-SP-L and GM-CSF. In an immunotherapy model, BALB/c mice inoculated with metastatic MUC1 transfected murine DA3 mammary tumor cells, exhibited significantly prolonged survival following vaccination with MUC1-SP-L. Our results indicate superior immunological and anti-tumor properties of MUC1-SP-L compared to previously published MUC1-derived epitopes.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1873-2518
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ltd. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
24
|
| pubmed:volume |
29
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
4676-86
|
| pubmed:meshHeading |
pubmed-meshheading:21570434-Aged,
pubmed-meshheading:21570434-Animals,
pubmed-meshheading:21570434-Cancer Vaccines,
pubmed-meshheading:21570434-Cell Proliferation,
pubmed-meshheading:21570434-Cytotoxicity, Immunologic,
pubmed-meshheading:21570434-Disease Models, Animal,
pubmed-meshheading:21570434-Female,
pubmed-meshheading:21570434-Histocompatibility Antigens,
pubmed-meshheading:21570434-Humans,
pubmed-meshheading:21570434-Immunotherapy,
pubmed-meshheading:21570434-Leukocytes, Mononuclear,
pubmed-meshheading:21570434-Male,
pubmed-meshheading:21570434-Mice,
pubmed-meshheading:21570434-Mice, Inbred BALB C,
pubmed-meshheading:21570434-Mice, Transgenic,
pubmed-meshheading:21570434-Middle Aged,
pubmed-meshheading:21570434-Mucin-1,
pubmed-meshheading:21570434-Neoplasms,
pubmed-meshheading:21570434-Protein Binding,
pubmed-meshheading:21570434-Rodent Diseases,
pubmed-meshheading:21570434-Survival Analysis
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.
|
| pubmed:affiliation |
Vaxil BioTherapeutics Ltd., 13 Einstein Street, Weizmann Science Park, Nes-Ziona 74036, Israel.
|
| pubmed:publicationType |
Journal Article
|